Canada:
Generic Damages In Life Sciences Patent Litigation: Strategic Considerations (Video Content)
18 February 2013
Gowling WLG
To print this article, all you need is to be registered or login on Mondaq.com.
In this presentation,
Christopher Van Barr and
Kiernan Murphy discuss strategic considerations relating to
generic damages in life sciences patent litigation.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from Canada
Update On Biosimilars In Canada – March 2024
Smart & Biggar
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access) since our March 2023 update.